Pembrolizumab
Immune therapy prevents bladder removal for some bladder cancer patients
A proportion of patients with difficult-to-treat non-metastatic bladder cancer benefit from immunotherapy with the drug pembrolizumab. This has been shown by international research, which Erasmus MC Cancer Institute co-led. Annually, researchers estimate this new therapy could save about 50 patients in the Netherlands from having their bladder removed.